


FORM PTO-1390 (REV. 1-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 0/97263 US	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/380695</b>	
INTERNATIONAL APPLICATION NO. PCT/EP98/01239		INTERNATIONAL FILING DATE 03-MAR-1998		PRIORITY DATE CLAIMED 05-MAR-1997	
TITLE OF INVENTION USE OF A 7ALPHA-METHYL-17ALPHA-ETHYNYL-ESTRANE DERIVATIVE FOR THE TREATMENT OF ATHEROSCLEROSIS					
APPLICANT(S) FOR DO/EO/US MEULMAN, Dirk G., and ZANDBERG, Pieter					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol> <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input type="checkbox"/> Other items or information:</li> </ol>					

U.S. APPLICATION NO. (If known, use 37 CFR 1.55) <b>09/380695</b>		INTERNATIONAL APPLICATION NO. PCT/EP98/01239		ATTORNEY'S DOCKET NUMBER 0/97263 US	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1070.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$930.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$790.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$720.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$98.00  ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	5 - 20 =		x \$22.00	\$	
Independent claims	1 - 3 =		x \$82.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				+	
SUBTOTAL =				\$	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$ 840.00	
				Amount to be refunded:	
				\$	
				charged:	
				\$ 840.00	
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.					
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>02-2334</u> in the amount of \$ <u>840.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2334</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:  Mary E. Gormley Akzo Nobel, N.V. 1300 Piccard Drive, Ste 206 Rockville, MD 20850					
				 SIGNATURE	
				<u>Mary E. Gormley</u> NAME	
				<u>34,409</u> REGISTRATION NUMBER	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

MEULMAN, Dirk G. and ZANDBERG, Pieter

Serial Number: not assigned Group Art Unit: not assigned

Filed: concurrently Examiner: not assigned

For: USE OF A 7 $\alpha$ -METHYL-17 $\alpha$ -ETHYNYL-ESTRANE DERIVATIVE FOR THE  
TREATMENT OF ATHEROSCLEROSIS

Corresponding to: PCT/EP98/01239, filed March 3, 1998

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

September 3, 1999


Sir:

Prior to the calculation of the fee in the above-identified application, please make the following amendments:

IN THE CLAIMS:

Please amend the claims as follows:

1. (amended) A method of inhibiting the atherosclerotic process, comprising administering to a mammal an effective amount  
[Use] of a 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-estrane derivative having the  
general formula I



wherein

$R_1 = H(OR_3) \text{ or } O;$

$R_2 = H \text{ or } (C_{1-18})Acyl;$

$R_3 = H \text{ or } (C_{1-18})Acyl;$

and the dotted line represents a double bond in the 4,5- or the 5,10-position [, for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis].

Claim 2, line 1, delete "Use" and insert therefor -- The method --.

Claim 3, line 1, delete "Use" and insert therefor -- The method --, and delete "or 2".

Claim 4, line 1, delete "Use" and insert therefor -- The method --.

Please cancel claim 5 without prejudice or disclaimer of the subject matter thereof.


Claim 6, please change "5" to -- 1 --.

REMARKS

Claims 1 - 4 and 6 are amended, and claim 5 is cancelled, hereby. Claims 1 - 4 and 6 are now pending.

It is believed that claims 1 - 4 and 6 recite a patentable improvement in the art. Favorable action is solicited. In the event any fees are required with this paper, please charge our Deposit Account No. 02-2334.

Respectfully submitted,

  
Mary E. Gormley  
Attorney for Applicants  
Registration No. 34,409

AKZO NOBEL N.V.  
1300 Piccard Drive, Suite 206  
Rockville, Maryland 20850-4373  
Tel: (301) 948-7400  
Fax: (301) 948-9751

MEG:mg

99meulman.pre

1

Ex. Mail No. EL358032416US

-3-

09/380695

**USE OF A 7 $\alpha$ -METHYL-17 $\alpha$ -ETHYNYL-ESTRANE DERIVATIVE FOR  
THE TREATMENT OF ATHEROSCLEROSIS**

5 The present invention relates to the use of a 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-  
estrane derivative for the manufacture of a medicament for the prophylaxis  
and the treatment of atherosclerosis.

10 The development of atherosclerosis starts with the accumulation of  
cholesterol in lipoproteins in the vessel wall and the subsequent development  
of fatty streaks (probably the earliest macroscopically recognizable lesions),  
which appear in the intima of the arterial vessel wall as focal collections of  
lipid-filled macrophages ("foam cells"). This process can progress in the  
formation of advanced lesions; foam cell necrosis and endothelial damage  
can occur leading to smooth muscle cell migration and proliferation, and to  
15 the formation of extracellular matrix. Thus atherosclerosis is the result of the  
interaction of a number of cell types in the vessel wall, in which increased  
plasma cholesterol can be the driving force (Davies, M.J., and Woolf, N.;  
"Atherosclerosis: what is it and why does it occur"; Brit. Heart J., 1993, 69  
(suppl.), S3-S11).

20 Coronary heart disease (CHD) is a consequence of atherosclerotic  
processes in the artery vessel wall. It is well known that the incidence of CHD  
in women in the reproductive stage of life is much lower than in men of similar  
age but that the risks sharply increase following the menopause.

25 The menopause has been associated with a large number of vasomotor,  
psychological and gynecological symptoms, part of which are characteristic  
for the perimenopausal period (climacteric). The menopause has been shown  
to be a risk factor for chronic diseases like osteoporosis and atherosclerosis.  
The sharply decreasing concentrations of estrogens, especially of estradiol  
(estra-1,3,5 (10)-triene-3,17-diol) and estron (3-hydroxy-estra-1,3,5 (10)-

triene-17-one), in post-menopausal women have been suggested to be related to these symptoms. Estrogen replacement therapy, through which the physiologic deficit of mainly estrogen is to be corrected, is gaining increasing acceptance as a means of alleviating climacteric symptoms in peri- and post-menopausal women and preventing osteoporosis. In addition, exogenous estrogen is reported to have a plasma cholesterol- and a LDL (low density lipoproteins)-cholesterol lowering effect and/or a plasma HDL (high density lipoproteins)-cholesterol increasing effect. These estrogen effects may be suggestive of a protective overall effect on the formation of atherosclerotic lesions.

However, clinically unopposed estrogen replacement therapy in post-menopausal women can increase the risk of endometrial hyperplasia and endometrial cancer. Therefore most therapies under study to date concern combined treatments with both an estrogen component and a progestagen component, which is added to negate the estrogen mediated risks (hormone replacement therapy). But progestagens can have adverse effects on the plasma lipoprotein concentrations and antagonize the beneficial effects of estrogen on the arterial vessel.

A synthetic steroid,  $7\alpha$ -methyl- $17\alpha$ -ethynyl- $17\beta$ -hydroxy-estra-5(10)-en-3-one (Org OD-14; tibolone), produced by Organon, The Netherlands, characterized by having a mixed profile of weak estrogenic, progestogenic and androgenic properties, has been shown to be clinically as effective as estradiol valerate or conjugated equine estrogens in reducing climacteric symptoms in peri-menopausal women. Tibolone has further been shown, like the long-term administration of estrogen, to provide substantial protection against the development of osteoporosis in post-menopausal women (Hannover, N. et al., J. Clin. Endocrinology and Metabolism (1996), 81, 2419-2422).

In addition, the effect of tibolone on plasma lipoprotein concentrations has been subject of several studies. In early studies, the overall changes in total


cholesterol, total glycerides or LDL and HDL cholesterol levels as a result of tibolone treatment after a 6-month period were reported to be not significant, implying that no negative side effects with respect to the early development of CHD were to be expected. Therefore, the compound was considered a useful alternative to conventional hormonal replacement therapy in post-menopausal women. (*Maturitas*, vol.8, no.4, 1986, pages 327-334). Studies assessing the long-term effects of tibolone treatment on lipid metabolism confirmed these findings. (see e.g. *Maturitas*, vol.12, no.1, 1990, pages 37-42). Other studies emphasize the negative effect of tibolone on HDL levels (a decrease, which is associated with an increased CHD risk), but describe a beneficial decreasing effect found on lipoprotein(a) (Lp(a)) levels, which according to the authors may help to restore the balance of (cardiovascular) risks associated with tibolone therapy. (*Acta Endocrinologica*, vol. 128, 1993, pages 259-262; *Eur. J. Clin. Chem. Clin. Biochem.*, Vol. 31, 1993, pages 645-650).

[Lp(a) is a cholesterol-rich lipoprotein which resembles LDL but is present only in trace amounts in most individuals. Those with elevated (>300 mg/l) serum Lp(a) concentrations are at high risk of CHD. Lp(a) is an independent risk marker for CHD.]

Nevertheless, the effect of long-term treatment with tibolone on HDL-cholesterol has been interpreted as less favorable with respect to its protective effect against cardiovascular disease, as compared with estrogen replacement therapy (Riggs, B.L., *J. Clin. Endocrinology and Metabolism* (1996), 81, 2417-2418).

Surprisingly, it has now been found that tibolone, prodrug forms thereof and certain metabolites thereof have strong anti-atherosclerotic properties. These properties are much more pronounced than those of e.g. 17 $\beta$ -estradiol.

The present invention therefore relates to the use of  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivatives having the general formula I



wherein

- 5  $R_1 = H(OR_3)$  or O;  $R_2 = H$  or  $(C_{1-18})$ Acyl;  $R_3 = H$  or  $(C_{1-18})$ Acyl;  
and the dotted line represents a double bond in the 4,5- or the 5,10-position,  
for the manufacture of a medicament for the prophylaxis or the treatment of  
atherosclerosis.

- 10 The compounds of the invention, more specifically the compounds of  
formula I, wherein  $R_1$  is H, OH or O, in particular those wherein  $R_2 = H$  and  
wherein the double bond is at the 5,10-position, and especially the compound  
wherein  $R_1$  is O,  $R_2$  is H and wherein the double bond is in the 5,10-position  
(tibolone; Org OD-14), have a very pronounced atheroprotective effect.

- 15 Thus, suitable  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivatives having general  
formula I which can be used according to the invention are, for example,  $7\alpha$ -  
methyl- $17\alpha$ -ethynyl- $17\beta$ -hydroxy-estra-5(10)-en-3-one (Org OD-14; tibolone),  
 $7\alpha$ -methyl- $17\alpha$ -ethynyl-estra-5(10)-en- $3\alpha$ , $17\beta$ -diol,  $7\alpha$ -methyl- $17\alpha$ -ethynyl-  
estra-5(10)-en- $3\beta$ , $17\beta$ -diol,  $7\alpha$ -methyl- $17\alpha$ -ethynyl- $17\beta$ -hydroxy-estra-4-en-3-  
20 one, and esters thereof. Preferred derivatives are tibolone and  $7\alpha$ -methyl-  
 $17\alpha$ -ethynyl-estra-5(10)-en- $3\alpha$ , $17\beta$ -diol. A particular preferred  $7\alpha$ -methyl-  
 $17\alpha$ -ethynyl-estrane derivative is tibolone.

The term acyl means an acyl group derived from an organic carboxylic acid having 1-18 carbon atoms, as is also indicated by the affix (C<sub>1-18</sub>).

Examples of such carboxylic acids are formic acid, acetic acid, propionic acid, butyric acid isobutyric acid, trimethylacetic acid, valeric acid, caproic acid, capric acid, undecylenic acid, lauric acid, palmitic acid, oleic acid, phenylacetic acid, phenylpropionic acid, benzoic acid, fumaric acid, maleic acid, succinic acid and citric acid. Preferred acyl groups have 1-6 carbon atoms, and most preferred is the acetyl group.

The 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-estrane derivatives according to formula I are known compounds. The compounds can thus be prepared as described, for example, in US Patent 3,340,279 and in US Patent 4,701,450 for 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-17 $\beta$ -hydroxy-estra-5(10)-en-3-one (tibolone).

The use of the compounds according to the present invention does not merely lead to an absence of negative cardiovascular side effects in hormone replacement therapy as might be derived from certain prior art sources, but the compounds even have an unexpected, significant and beneficial atheroprotective effect. The 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-estrane derivatives according to the invention, and pharmaceutical preparations based thereon, have a beneficial effect on the cholesterol accumulation in the vessel wall, the fatty streak formation and the advanced lesion formation.

These direct effects on the vessel wall were observed in a general accepted, relevant and validated atherosclerosis model in rabbits. Contrary to expectation, in view of the weak estrogenic activity of the compounds of the invention, the remarkable and unpredicted strong atheroprotective effect of the compounds of the invention has been demonstrated down to very low doses and were much stronger in comparison with the atheroprotective effect of 17 $\beta$ -estradiol.

Although the compounds of invention -in contrast to estradiol- can in humans lower the plasma concentration of lipoprotein Lp(a), this can not be

the explanation for the much more pronounced atheroprotective effect. In contrast to humans in rabbits no Lp(a) is present in the plasma (rabbits do not synthesize Lp(a); see Science, vol. 246, 1989, p.904-910). Therefore the strong atheroprotective effect of the compounds of this invention in (atherosclerotic) rabbits are independent of an effect on Lp(a). Consequently, when in humans a decrease in Lp(a) plays an additional role in atheroprotection, then the unexpected strong atheroprotective effect observed in rabbits might even be stronger in humans.

The  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivatives of the present invention thus have a strong intrinsic atheroprotective potential and are therefore not only useful drugs in hormone replacement therapy of peri- and post-menopausal women, but they are also suitable for therapeutic use in the treatment of atherosclerosis in mammals, both male and female, of all ages. Additionally, they can also be used prophylactically to prevent atherosclerosis.

The present invention therefore provides a method of inhibiting the process of atherosclerosis comprising administering to a mammal, preferably to a human, an atheroprotective amount of a  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivative having the general formula I, as previously defined.

The compounds of the present invention may be used alone or in combination with each other or with one or more other atheroprotective drugs, provided that they do not negatively interfere with each others action. A medical professional will know which drugs and combinations to choose.

The  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivatives according to the invention may be administered enterally or parenterally and for humans in a daily dosage of 0.05 - 10 mg, preferably 0.1-2.5 mg.

A daily dose can be administered in one or more dosage units through for example the oral, the rectal, the sublingual route, the nasal route or through

the skin (for example, transdermal patches, or in the form of a cream).  
Preferably a single dosage unit a day is administered by the oral route.  
Alternatively, a controlled release preparation, releasing the daily required  
total dose as defined above, can be used. Controlled release preparations  
5 can be taken by the oral route, or are preferably applied in the form of a  
subcutaneous implant.

The pharmaceutical preparations for use according to the invention can  
be prepared in accordance with standard techniques such as for example are  
10 described in the standard reference, Gennaro et al. (Ed.), Remington's  
Pharmaceutical Sciences, (18<sup>th</sup> ed. Mack Publishing Company, 1990, e.g.  
Part 8: Pharmaceutical Preparations And Their Manufacture). For the  
purpose of making the pharmaceutical preparations according to the  
invention, the 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-estrane derivatives according to  
15 formula I, or pharmaceutically acceptable salts thereof, are mixed with or  
dissolved in a pharmaceutical acceptable carrier. Examples of such  
preparations are tablets, pills, suppositories, (micro-)capsules, powders,  
emulsions, creams, ointments, suspensions, solutions, implants, or sprays.

Examples of pharmaceutically acceptable carriers are: starch (for  
20 example potato or corn starch), sugars (for example lactose), lubricants (for  
example magnesium stearate), binders (for example amylopectine or  
polyvinyl pyrrolidone), water, alcohol, glycerol and its derivatives, vegetable-,  
animal- and mineral oils and fats, fatty alcohols, silicones, polyalkylene  
glycols, cellulose derivatives, silica, dispersants, emulsifiers, surfactants,  
25 anti-oxidants, colorants and preservatives. In fact, any conventional  
pharmaceutical carrier that does not interfere with performance of the active  
ingredient can be used in the preparations according to the present  
invention.

Pharmaceutical preparations of the preferred  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivative of the invention, i.e.  $7\alpha$ -methyl- $17\alpha$ -ethynyl- $17\beta$ -hydroxy-estra-5(10)-en-3-one (Org OD-14; tibolone), are preferably prepared using the crystalline pure monoclinic ( $P2_1$ ) form of Org OD-14, because of its improved stability, bioavailability and shelf-life. The synthesis and use in a pharmaceutical preparation of this monoclinic derivative of Org OD-14 is disclosed in European Patent No. 0,389,035B1.

The invention is illustrated by the following examples:

#### General

The atheroprotective properties of  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivatives according to formula I are revealed in a cholesterol fed rabbit model wherein the effects of the compounds on the atherogenesis in female ovariectomized rabbits are established. The model is considered relevant to the human atherosclerotic process, because the cellular events occurring during the development of the atherosclerotic lesions during the atherogenic diet are similar to those observed in different stages of atherosclerotic processes in coronary arteries. Rabbits, however, do not have Lp(a) in their plasma.

#### Example 1

Tablets were prepared from a basic granulate containing lactose (100 mg per tablet) and dried potato starch (10 mg per tablet). The base granules were prepared by mixing the lactose with a portion of the starch. The remainder of the starch was mixed to a slurry with water and added to the mixture. The whole was granulated and dried. These base granules were mixed with ascorbyl palmitate (0.2 mg per tablet) and with either one of OD14 (2 mg or 6 mg per tablet) or  $17\beta$ -estradiol (4 mg per tablet), sieved, finely mixed with magnesium stearate (0.5 mg per tablet) and then tableted.

Example 2.

An experiment was performed with 7 groups of sexually mature, virgin female New Zealand White rabbits (Harlan, Zeist, The Netherlands), age 7-9 months and weighing approximately 3 kg (number of rats per group: 13-14). During the acclimatization period the rabbits were fed a diet of standard commercial rabbit chow LKK20 (Hope Farms, Woerden, The Netherlands). Three weeks prior to the start of the experiment the animals were anaesthetized and underwent bilateral ovariectomy (OVX) or were sham operated. After three weeks, at the start of the experiment, the rabbits were randomized over the treatment groups. In all animals de-endothelialisation of a segment of the left carotid artery was applied by using the air-drying technique (Fishman, J.A. et al., "Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening", Lab. Invest. 1975, 32, 339-351; and Lafont, A. et al., "Restenosis and experimental angioplasty: Intimal, medial and adventitial changes associated with constructive remodeling", Circulation Research, 1995, 76, 996-1002)

The animals were randomly allocated into 7 experimental groups using a randomized block design. The groups were fed an atherogenic diet (commercial rabbit chow (LKK20) enriched with 0.4 grams cholesterol, 3.75 grams coconut oil and 3.75 grams peanut oil per 100 grams). One group was fed the standard rabbit chow (LKK20). Food intake was restricted to 80 grams daily.

The treatments (Table I) were daily administered orally as a tablet, prepared as in Example 1. Groups 1, 2 and 3 were on a daily placebo treatment. Groups 4-5 were treated with 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-17 $\beta$ -hydroxy-estra-5(10)-en-3-one (OD-14; tibolone; 6 or 2 mg daily); group 6 with 17 $\beta$ -estradiol (4 mg daily). Group 7 was on treatment with 17 $\beta$ -estradiol decanoate (150  $\mu$ g in 1 ml arachis oil injected subcutaneously once a week).

Table I: Design of the experiment

	Group	n	Treatment*	Dose	Diet	OVX
5	1	14	Placebo		cholesterol	Yes
	2	13	Placebo		cholesterol	No
	3	13	Placebo		normal	Yes
	4	14	Org OD14	6 mg	cholesterol	Yes
	5	13	Org OD14	2 mg	cholesterol	Yes
10	6 E2	14	Estradiol	4 mg	cholesterol	Yes
	7 E2D	14	Estradiol decanoate	150 µg	cholesterol	Yes

\*The doses were administered orally except for group 7 in which the dose was injected subcutaneously once a week.

During the experiment blood samples were drawn out of the central ear artery after sedation with Hypnorm (0.1 ml i.m.) (Janssen Pharmaceutics, Beerse, Belgium) before the daily treatment, at week 4,8,12,16 and 20, to monitor the plasma cholesterol levels and to measure, at week 17, plasma estradiol levels and plasma tibolone levels.

Twenty weeks after the start of the experiment animals were anaesthetized by an i.m. injection of Hypnorm (0.5 ml/kg). After blood sampling the rabbits were killed by exsanguination and the aortic arch, uterus and carotid artery removed for further analyses.

### Example 3

In addition to example 2 an additional experiment was performed with two lower doses of Org OD14 and a higher dose of estradiol decanoate. These groups together with a placebo group and a control group resulted in an experiment with 5 groups (see table II).

The procedures were identical to those in example 2.

Three weeks prior to the start of the experiment the animals were ovariectomized. At the start of the experiment the carotid artery was de-endothelialised using the air-drying technique. The normal rabbit chow was replaced by the atherogenic diet except for the control group which received during the experiment the normal rabbit chow.

Table II: Design of the experiment

Group	n	Treatment*	Dose	Diet	OVX
1	22	Placebo		cholesterol	Yes
2	13	Placebo		normal	Yes
3	13	Org OD14	0.6 mg	cholesterol	Yes
4	11	Org OD14	0.15 mg	cholesterol	Yes
5 E2D	14	Estradiol decanoate	300 µg	cholesterol	Yes

\*The doses were administered orally except for group 5 in which the dose was injected subcutaneously once a week.

The treatments (table II) of group 1, 2, 3 and 4 were daily administered orally as a tablet, prepared as in example 1. The doses of Org OD14 per tablet, however, were 0.6 mg and 0.15 mg respectively. Group 5 was on treatment with 17β-estradiol decanoate (300 µg in 1 ml arachis oil injected subcutaneously once a week).

Twenty weeks after the start of the experiment was ended in the same manner as described in example 2.

## EVALUATION OF ATHEROSCLEROSIS

### ***A: Fatty streaks***

The aortic arch was dissected free, opened longitudinally and fixed in 2% paraformaldehyde. The tissue was then stained for lipids using 0.3% (w/v) Sudan Red. Colour photographs were taken of all segments. The percentage coverage of the aortic arch (Table II) with fatty streaks was assessed using image analysis (Context Vision Systems AB, Linköping, Sweden).

### ***B: Vessel wall cholesterol measurement***

After fatty streak measurement the aortic arch was minced in a dismembrator (Mikro-Dismembrator, B. Braun, Melsungen, Germany), followed by a lipid extraction according to the method of Bligh and Dyer (Can. J. Biochem. Biophys. 1959, 37, 911-917). The total cholesterol content in the chloroform/methanol extraction solution was, after evaporation under nitrogen and dissolution in methanol, determined using enzymatic CHOD-PAP method (cat. no. 1442341, Boehringer Mannheim, Germany) and evaluated in a spectrophotometer (wavelength 500 nm). The amount of protein in the tissue was determined by the method of Lowry.

### ***C: Intimal thickening after de-endothelialisation***

The left (airdried) carotid artery was dissected and fixed in 2% paraformaldehyde containing 6.8% glucose. The right carotid artery was used as comparison. After fixation the tissue was divided in blocks with a length of 2 mm and embedded in paraffin (Paraplast plus®, Sherwood Medical Co, St. Louis, USA) using an automated tissue processor (Hypercenter XP, Shandon).

To measure intimal thickening (using image analysis) a specific staining method and a belonging image analysis application have been developed.

Measurements were performed on 2  $\mu$ m transverse sections which were treated with elastase (Serva Feinbiochemica GmbH, Heidelberg, Germany) prior to elastin staining with Lawson solution (Boom, Meppel, the Netherlands) and light green (Sigma). Subsequently sections were airdried and mounted in Pertex (Leica GmbH, Nussloch, Germany).

For morphological study both methylene blue/Azur II and hemotoxylin/eosin stained (2  $\mu$ m) transverse sections were used. Smooth muscle cells and macrophages were detected with respectively  $\alpha$ -actin antibodies (Sigma) and anti-macrophage antibodies (RAM11, DAKO, Glostrup, Denmark). For detection of bound antibodies goat anti-mouse ultra small gold conjugated secondary antibodies (Aurion, Wageningen, The Netherlands) and the immunogold-silver enhancement technique (SilvEnhance-LM Kit, Zymed) were used.

Images of the sections were obtained using a black and white video camera. (MX-5, Adimec Image Systems BV, Eindhoven) mounted upon a light microscope (Axioplan, Zeiss, Jena, Germany). The video image was digitized and the intimal thickening was measured using a semi-automated image analysis application (Context Vision Systems AB, Linköping, Sweden).

Statistics: Data were expressed as mean  $\pm$  S.E.M. unless otherwise specified. For testing statistical significance the Analysis of Variance (ANOVA) was used. The data were logarithmically transformed to normalize variations. A value of  $P < 0.05$  was considered to be significant.

**RESULTS (example 2, Table III)**

After 20 weeks of diet and of daily treatment, necropsy was performed to determine the accumulation of cholesterol and fatty streaks in the aortic arch and the advanced lesions in the carotid artery. Moreover the weight of the uterus was determined. The results are presented in the Table III.

No significant difference in any of the variables measured were found between the ovariectomized animals (group 1) and the non-ovariectomized animals (group 2). This confirms that in the non-ovariectomized female rabbits the endogenous basal plasma estradiol levels are low.

Oral administration of  $17\beta$ -estradiol (4 mg per day; group 6; E2) resulted in peak plasma estradiol levels of 238 pg/ml at 1h after administration, which was reduced to 18 pg/ml after 24 hours. Subcutaneous administered estradiol decanoate (150  $\mu$ g per week; group 7; E2D) resulted in rather stable plasma estrogen levels over the day (about 60 to 70 pg/ml). The plasma levels indicate that both modes of administration of estradiol lead to effective plasma levels.

Using the human doses of estradiol and Org OD14 used for HRT treatment and corrected for the caloric intake it was expected that in the rabbit an oral dose of 4 mg estradiol is about equipotent with 6 mg Org OD14.

Measurement of the plasma levels in the rabbit showed that Org OD14 at a dose of 6 mg per day resulted in plasma concentrations of Org OD14 comparable to those obtained in women with the clinical dose of 2.5 mg.

Org OD14 (2 and 6 mg per day) increased uterus (estrogenic activity) weight to a similar extent as both estradiol treatments (E2 or E2D), confirming the equipotency of the doses used.

Despite this equipotent activity of the estrogen and Org OD14 treatments on the uterus the effect on cholesterol accumulation in the aorta and lesion formation in the aorta were different: 17 $\beta$ -estradiol (E2) treatment did not lead to a reduction in cholesterol accumulation, 17 $\beta$ -estradiol decanoate (E2D) treatment reduced cholesterol accumulation in the aortic arch with 46%, while Org OD 14 completely prevented cholesterol accumulation in the aortic arch at both concentrations studied.

17 $\beta$ -estradiol (E2) and 17 $\beta$ -estradiol decanoate (E2D) did not affect plasma cholesterol levels while Org OD14 strongly reduced the plasma cholesterol levels.

Fatty streak formation in the aortic arch was only slightly reduced by estrogen treatment while Org OD14 (nearly) completely prevented the fatty streak formation.

17 $\beta$ -estradiol (E2) had no effect on advanced lesion formation, following mechanical de-endothelisation, while 17 $\beta$ -estradiol decanoate (E2D) reduced advanced lesion formation. Histology showed that in placebo animals on a cholesterol diet the lesions consisted of smooth muscle cells and foam cells while in animals on a normal diet only smooth muscle cell were observed in the lesions. Histology of the E2D treated animals showed that the lesions still consisted of smooth muscle cells and foam cells. Org OD14 strongly inhibited the formation of advanced lesions. Lesion formation was even less than in the animals on a normal diet (control group). Histology showed that the lesions consisted only of smooth muscle cells.

## RESULTS (example 3, Table IV)

In example 2 we found that 2 and 6 mg Org OD14 in the rabbit strongly inhibited the development of atherosclerotic lesion formation. These effects were unexpectedly much more pronounced than of estradiol or estradiol decanoate while there was an equipotent estrogenic activity on the uterus.

In example 3 we tested Org OD14 at two lower doses (0.6 and 0.15 mg orally once daily) and estradiol decanoate at a higher dose (300 µg s.c. once weekly). The aim was to obtain a dose of Org OD14 which had equipotent anti-atherosclerotic effects as estradiol decanoate.

5 The results show that Org OD14 at 0.6 mg still nearly completely prevented atherosclerotic lesion formation. A two times higher dose of estradiol decanoate (compared to table III) still only partially inhibited atherosclerotic lesion formation.

10 A dose between 0.60 mg-0.15 mg Org OD14 will show about equipotent anti-atherosclerotic effects as the 300 µg dose of estradiol decanoate. The effect on the uterus, however, was completely different. While the uterus weight increased from 0.054 to 0.132 grams (144 % increase) for Org OD14 it increased to 0.505 grams (835% increase) per 100 grams body weight for estradiol decanoate.

## 15 CONCLUSION

The results of example 2 demonstrate that while 17β-estradiol, 17β-estradiol decanoate and Org OD14, in clinically equivalent doses, are approximately equally potent on the uterus growth in rabbits, the beneficial effects of OD14  
20 on plasma cholesterol, cholesterol accumulation in the aortic arch and advanced lesion formation in the carotid artery, are much more pronounced than those of 17β-estradiol.

Furthermore, as demonstrated in example 3, at a dose between ten to forty times lower (0.60-0.15 mg) Org OD14 had about equipotent anti-  
25 atherosclerotic effects as a two times higher dose of estradiol decanoate (300 µg). The estrogenic effect (increase in uterus weight) for estradiol decanoate, however, was much more pronounced than for Org OD14.

These results indicate that Org OD14 has intrinsically the potential to be clinically effective for the prevention and treatment of atherosclerosis.

**Table III**

The effect of different treatments on the atherogenic diet induced morphologic changes in the aortic arch and carotid artery as well as the influence on body weight, plasma cholesterol and uterus weight as measured at the time point of necropsy (20 weeks after the start of the experiment).

	Controle Group 3	Placebo Group 1	Org OD14 Group 4	Org OD14 Group 5	Estradiol Group 6	Estradiol decanoate Group 7
Number of Rabbits	13	9	13	12	13	11
Body weight in grams	2831 ± 50	2683 ± 95	2758 ± 41	2815 ± 50	2831 ± 58	2973 ± 52
Uterus weight per 100 grams body weight	0.08 ± 0.01	0.09 ± 0.01	0.24 ± 0.06 *	0.29 ± 0.03 *	0.31 ± 0.02 *	0.37 ± 0.04 *
Mean plasma cholesterol exposure in mmol/L/day	1.0 ± 0.1 *	26.9 ± 3.3	11.2 ± 1.5 *	9.0 ± 1.3 *	27.7 ± 2.8	30.0 ± 3.7
Cholesterol level in aortic arch in nmol/mg protein	45 ± 5 *	590 ± 126	52 ± 9 *	61 ± 11 *	521 ± 99	318 ± 58 *
Fatty streak in aortic arch in % of arcus covered	0.3 ± 0.2 *	34.5 ± 6.8	1.3 ± 0.8 *	1.4 ± 0.7 *	25.5 ± 5.2	28.1 ± 4.1
Advanced lesions in carotid artery: intimal surface in mm <sup>2</sup>	0.22 ± 0.03 *	0.44 ± 0.10	0.13 ± 0.03 *	0.14 ± 0.02 *	0.30 ± 0.06	0.23 ± 0.06 *

\* p < 0.05 compared with placebo (group 1)

**Table IV**


The effect of Org OD14 (0.6 and 0.15 mg orally per rabbit once daily) compared to a two times higher dose of estradiol decanoate (300 µg subcutaneously per rabbit once weekly) compared to the dose in table III on the atherogenic diet induced morphologic changes in the aortic arch and carotid artery as well as the influence on body weight, plasma cholesterol and uterus weight as measured at the time point of necropsy (20 weeks after the start of the experiment).

	Controle	Placebo	Org OD14 0.6 mg	Org OD14 0.15 mg	Estradiol decanoate
<b>Number of Rabbits</b>	13	22	13	11	14
<b>Body weight in grams</b>	2869 ± 38	2882 ± 73	3008 ± 58	2850 ± 42	3093 ± 60
<b>Uterus weight per 100 grams body weight</b>	0.051 ± 0.009	0.054 ± 0.007	0.224 ± 0.016 *	0.132 ± 0.013 *	0.505 ± 0.075 *
<b>Mean plasma cholesterol exposure in mmol/L/day</b>	1.3 ± 0.4 *	38.9 ± 2.5	12.8 ± 1.2 *	20.7 ± 1.5 *	23.0 ± 2.0 *
<b>Cholesterol level in aortic arch in nmol/mg protein</b>	51 ± 9 *	636 ± 53	97 ± 23 *	297 ± 67 *	225 ± 69 *
<b>Fatty streak in aortic arch in % of arcus covered</b>	1.0 ± 0.7 *	41.9 ± 2.8	5.9 ± 2.4 *	23.5 ± 5.3 *	14.2 ± 3.2 *
<b>Advanced lesions in carotid artery: intimal surface in mm<sup>2</sup></b>	0.13 ± 0.02 *	0.31 ± 0.07	0.14 ± 0.01 *	0.24 ± 0.05	0.18 ± 0.02 *

\* p< 0.05 compared with placebo (group 1)

## Claims:

1. Use of a  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivative having the general formula I



wherein

$R_1 = H(OR_3)$  or O;

$R_2 = H$  or  $(C_{1-18})Acyl$ ;

$R_3 = H$  or  $(C_{1-18})Acyl$ ;


and the dotted line represents a double bond in the 4,5- or the 5,10-position, for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis.

2. Use according to claim 1, wherein  $R_1 = H, OH$  or O.

3. Use according to claim 1 or 2, wherein  $R_2 = H$  and the dotted line represents a double bond in the 5,10-position.

4. Use according to claim 1, wherein the a  $7\alpha$ -methyl- $17\alpha$ -ethynyl-estrane derivative is  $7\alpha$ -methyl- $17\alpha$ -ethynyl- $17\beta$ -hydroxy-estra-5(10)-en-3-one.

5. A method of inhibiting the process of atherosclerosis comprising administering to a mammal an atheroprotective amount of a 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-estrane derivative having the general formula I



5 wherein

$R_1 = H(OR_3)$  or  $O$ ;

$R_2 = H$  or  $(C_{1-18})Acyl$ ;

$R_3 = H$  or  $(C_{1-18})Acyl$ ;

and the dotted line represents a double bond in the 4,5- or the 5,10-position.

10

6. The method according to claim 5 wherein the mammal is human.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 31/565	A1	(11) International Publication Number: WO 98/39012 (43) International Publication Date: 11 September 1998 (11.09.98)
--	----	---

(21) International Application Number: PCT/EP98/01293

(22) International Filing Date: 3 March 1998 (03.03.98)

(30) Priority Data:  
97200646.4 5 March 1997 (05.03.97) EP

(34) Countries for which the regional or international application was filed: NL et al.

(71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MEULEMAN, Dirk, Gerrit [NL/NL]; Beethovengarde 69, NL-5344 HC Oss (NL). ZANDBERG, Pieter [NL/NL]; Uitstroom 1, NL-5345 RX Oss (NL).

(74) Agent: HOGENBIRK, M.; P.O. Box 20, NL-5340 BH Oss (NL).

(81) Designated States: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

## Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF A 7 $\alpha$ -METHYL-17 $\alpha$ -ETHYNYL-ESTRANE DERIVATIVE FOR THE TREATMENT OF ATHEROSCLEROSIS

## (57) Abstract

The invention relates to the use of a 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-estrane derivative having general formula (I) wherein R<sub>1</sub> = H(OR<sub>3</sub>) or O; R<sub>2</sub> = H or (C<sub>1-18</sub>)Acyl; R<sub>3</sub> = H or (C<sub>1-18</sub>)Acyl; and the dotted line represents a double bond in the 4,5- or the 5,10-position for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis.



# DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled: ***"Use of a 7 $\alpha$ -methyl-17 $\alpha$ -ethynyl-estrane derivative for the treatment of atherosclerosis"***

the specification of which

[CHECK ONE]

[ ] is attached hereto

[ ] was filed on \_\_\_\_\_ as Application Serial No.

\_\_\_\_\_ and was amended on \_\_\_\_\_

if applicable]

[X] as filed under the Patent Cooperation Treaty on March 03, 1998

Serial PCT/EP98/01293, The United States of America being designated.

hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined Title 37, Code of Federal Regulations Section 1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign applications(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority claimed
<u>97200646.4</u>	<u>EP</u>	<u>05 / 03 / 1997</u>	<u>X</u> Yes <u>    </u> No
Number	Country	Day/Month/Year filed	
		<u>    </u> / <u>    </u> / <u>    </u>	<u>    </u> Yes <u>    </u> No
Number	Country	Day/Month/Year filed	
		<u>    </u> / <u>    </u> / <u>    </u>	<u>    </u> Yes <u>    </u> No
Number	Country	Day/Month/Year filed	

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the patent and Trademark

Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which

became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,772, Mary E. Gormley, Registration No. 34,409, Gregory R. Muir, Registration No. 35,293 and Michael G. Sullivan, Registration No. 35,377.

Please address all communications to:

William M. Blackstone  
AKZO NOBEL  
1300 Piccard Drive #206  
Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor 1-00 Dirk, Gerrit Meuleman

Inventor's signature [Signature]

Citizenship Dutch NLX

Date 21/09/1999

Residence and P.O. Address Beethovengarde 69, 5344 HP OSS - The Netherlands CCM

Full name of second joint inventor 2-00 Pieter Zandberg

Inventor's signature [Signature]

Citizenship Dutch NLX

Date 21/09/1999

Residence and P.O. Address Uitstroom 1, 5345 RX OSS - The Netherlands

Full name of third joint inventor \_\_\_\_\_

Inventor's signature \_\_\_\_\_

Date

Citizenship \_\_\_\_\_

Residence and P.O. Address \_\_\_\_\_